GlaxoSmithKline (GSK) has signed an agreement with Russian company JSC Binnopharm over the secondary manufacture of a number of its vaccines.
The alliance will see GSK provide JSC Binnopharm with bulk vaccines, as well as the technology and expertise to enable the local production of cervical cancer, rotavirus and pneumococcal vaccines.
GSK said the deal should help Russia to update its National Immunisation Calendar by providing additional vaccination against common infections.
The agreement, which was signed in Moscow during the session of the Russian-British Intergovernmental Steering Committee (ISC) for Trade and Investment, was endorsed by business secretary Vince Cable.
He said the alliance "emphasises the strong pharmaceutical links that the UK shares with Russia".
Mr Cable added: "Not only does this demonstrate trust between companies sharing their knowledge across borders, but ordinary people will see the benefits."
JSC Binnopharm will be responsible for gaining approval for the supply of GSK vaccines to the Russian public market.
Earlier this month, GSK extended its collaborative agreement with Fiocruz of Brazil to research and develop new medicines for tropical diseases.